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Little is understood about the occurrence of somatic
genomic alterations in normal tissues and their sig-
nificance in the context of disease. Here, we identi-
fied potential somatic copy number alterations
(pSCNAs) in apparently normal ovarian tissue and
peripheral blood of 423 ovarian cancer patients.
There were, on average, two to four pSCNAs per
sample detectable at a tissue-level resolution,
although some individuals had orders of magnitude
more. Accordingly, we estimated the lower bound
of the rate of pSCNAs per cell division. Older individ-
uals and BRCA mutation carriers had more pSCNAs
than others. pSCNAs significantly overlapped with
Alu and G-quadruplexes, and the affected genes
were enriched for signaling and regulation. Some of
the amplification/deletion hotspots in pan-cancer
genomes were hot spots of pSCNAs in normal tis-
sues as well, suggesting that those regions might
be inherently unstable. Prevalence of pSCNA in
peripheral blood predicted survival, implying that
mutations in normal tissues might have conse-
quences for cancer patients.
INTRODUCTION
Starting at fertilization of the egg, during the course of develop-
ment and aging, somatic cells accumulate mutations in their
genome. Although somatic mutations have been predominantly
studied in the context of cancer and aging, increasing evidence
suggests that apparently normal cells also carry a considerable
burden of somatically acquired mutations, and those mutations
might have subtle phenotypic consequences (De, 2011; Poduri
et al., 2013; Youssoufian and Pyeritz, 2002). For instance,
somatic mutations can contribute to disease onset and ‘‘missing
heritability’’ in some complex diseases (Bonnefond et al., 2013;
De, 2011; Manolio et al., 2009). The aging-associated burden1310 Cell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authorsof somatic mutations is expected to decrease the overall fitness
of cells in somatic tissues, facilitating selection for neoplastic
cells and increasing cancer incidence in older individuals
(DeGregori, 2013). Indeed, two recent population genetics
studies by Jacobs et al. (2012) and Laurie et al. (2012) have
shown that detectable clonal mosaicism is linked to cancer
risk and aging. Although individual somatic cells in a tissue
harbor diverse genetic changes, those that are detected at
tissue level, i.e., present in a considerable fraction of cells, are
expected to have noticeable consequences. How common are
these somatic mutations? By widely accepted estimates,
somatic cells accumulate 107–108 point mutations per base
per generation (Araten et al., 2005; Campbell and Eichler,
2013; Lupski, 2007). It was recently suggested that half or
more of the point mutations in cancers of self-renewing tissues
might originate prior to tumor initiation (Tomasetti et al., 2013).
And yet, there are only limited estimates (Jacobs et al., 2012;
Laurie et al., 2012; Pham et al., 2014) of the prevalence of other
classes of somatic genomic alterations, such as amplifications
and deletions, available for apparently normal tissue types.
Moreover, the effects of somatic genomic alterations in appar-
ently normal tissue in the context of diseases such as cancer
are poorly understood. Recently, large-scale cancer genomics
initiatives (Collins and Barker, 2007; Kanchi et al., 2014; Cancer
Genome Atlas Research Network, 2011, 2012; Zack et al., 2013)
have opened up opportunities to test such hypothesis.
Here, we have carried out a large-scale, genome-wide survey
of potential somatic amplifications and deletions in apparently
normal tissues (potential somatic copy number alterations in
apparently normal tissues [pSCNAsnorm]) of patients with cancer
and assessed their significance toward disease outcome. We
chose to focus on the pSCNAsnorm that are detectable by micro-
arrays at tissue-level resolution. We map these genomic
changes in apparently normal peripheral blood and ovarian tis-
sue in a large cohort of ovarian cancer patients (Cancer Genome
Atlas Research Network, 2011) by comparing pairs of tumor and
matched normal genomes and (1) provide an estimate of the
prevalence of pSCNAsnorm, identifying specific patterns associ-
ated with age or germline BRCA mutations, (2) study the
genomic context of these pSCNAsnorm, (3) compare and contrast
the genome-wide patterns of somatic copy number alterations in
normal (pSCNAsnorm) and cancer genomes, and (4) evaluate
whether the burden of somatic mutations in apparently normal
tissue predict tumor progression and survival in the same
individual.
RESULTS
We obtained genomic and clinical data for 423 ovarian cancer
patients from the Cancer Genome Atlas (Cancer Genome Atlas
Research Network, 2011) and inferred the pSCNAsnorm by
comparing the paired normal and tumor genomes, after adopt-
ing appropriate quality control steps to exclude false positives
and remove technical artifacts (Experimental Procedures; Sup-
plemental Module 1). These pSCNAsnorm were detectable at a
tissue-level resolution, indicating either early developmental
origin, selection for these genomic alterations, or the effects of
random drift. Our final data set had 279 potential somatic
amplifications (pAmpnbl) and 328 potential somatic deletions
(pDelnbl) in 314 normal peripheral blood samples (collectively
referred to as pSCNAnbl) and 137 potential somatic amplifica-
tions (pAmpnov) and 357 potential somatic deletions (pDelnov) in
109 normal ovarian tissue samples (collectively referred to as
pSCNAnov).
Prevalence of Potential Somatic Amplifications and
Deletions
We found that there were typically four and two detectable
pSCNAsnorm per ovarian tissue and peripheral blood sample,
respectively, although the number of pSCNAnorm varied over
two orders of magnitude between the samples (ovary: max:
122, min: 0; blood: max: 53, min: 0). The number of pSCNAsnorm
per sample followed Poisson distributions (pSCNAnov Pois[l =
4.53] in ovary; pSCNAnblPois[l = 1.93] in peripheral blood). The
numbers of amplifications and deletions per sample were gener-
ally comparable. Anyhow, these are probably very conservative
estimates of the number of somatic genomic alterations,
because we were unable to detect all pSCNAsnorm using our
approach (see Experimental Procedures for details). We also
note the potential caveats in Supplemental Module 2. We pre-
dicted a parsimonious estimate of the lower bound of the rate
of somatic genomic alterations in peripheral blood is 105–
106 per locus per somatic cell division (depending on the model
chosen; Experimental Procedures; Supplemental Module 2),
which is comparable to the germline estimates (104–106 per
locus per generation; Campbell and Eichler, 2013; Lupski,
2007) and those derived from single-cell genome sequencing
of cancer cells (Voet et al., 2013; Supplemental Module 2).
The Burden of Detectable pSCNAs Increases with Age
Integrating the tissue-level pSCNAnbl data together with the age
of the patients (Cancer Genome Atlas Research Network,
2011;who had no BRCA mutations), we found that the older
patients on average had more potential genomic alterations
than the younger patients (Figure 1C). For instance, the patients
of age 70 years and above had significantly more pSCNAsnbl
compared to those of age less than 40 years (Mann Whitney
U test; p value 3.933 102); the trend was not apparent betweenC40 and 70 years. We find similar results for potential somatic
amplifications and deletions, independently (Supplemental
Module 3). The number of BRCA mutation carriers was too small
to warrant a similar analysis only on this select group of patients.
In any case, our results concur with recent reports (Jacobs et al.,
2012; Laurie et al., 2012) and show that the burden of amplifica-
tions and deletions increases with age, a trend that is similar to
that reported for point mutations, loss of heterozygosity, and
ploidy changes (Maslov et al., 2013; Matsuo et al., 1982; Peder-
sen et al., 2013a; Tomasetti et al., 2013; Vogelstein et al., 2013).
Age-dependent increases in genomic changes could reflect the
occurrence of new mutations, alterations in selection (positive
selection for some changes and/or reduced purifying selection
against others), and/or bottlenecks that lead to reduced clonal
diversity.
BRCA Mutation Carriers Harbor More Potential Somatic
Amplifications and Deletions
BRCA mutation carriers are at a higher risk of several different
types of cancer (Friedenson, 2007; Moran et al., 2012). To test
whether BRCA mutation carriers have more genomic alterations
in apparently normal tissue than noncarriers, we grouped the
Cancer Genome Atlas (TCGA) samples based on their BRCA
mutation status (Cancer Genome Atlas Research Network,
2011) as those with (1) BRCA (BRCA1 or BRCA2) germline muta-
tions, (2) BRCA somatic mutations, and (3) no BRCA mutations.
Comparing the number of pSCNAsnbl between the three groups,
we found that the number of detectable pSCNAsnbl is signifi-
cantly higher in the samples with BRCA germline mutation
compared to those with no mutations (Mann Whitney U test;
p value: 1.61 3 102). In contrast, individuals with somatic
BRCA mutations in their ovarian cancer did not exhibit any in-
crease in pSCNAsnbl compared to individuals with no BRCA
mutations. We found similar results in ovarian tissue—the num-
ber of pSCNAsnov was higher in the germline BRCA mutation
carriers compared to those with no BRCA mutations, but the
statistical significance was modest due to small sample size
(Mann Whitney U test; p value > 0.05). We found consistent
results when repeating the analysis after grouping the samples
by age and also when analyzing pAmpnbl, pDelnbl, pAmpnov,
and pDelnov separately (Supplemental Module 3). Taken
together, on average, BRCA mutation carriers harbor more
potential somatic amplifications and deletions in apparently
normal tissues compared to those with no BRCA mutations.
Our findings are consistent with the report that BRCA1 haploin-
sufficiency promotes genomic instability in nonmalignant cells
(Konishi et al., 2011) and provide a plausible explanation for
higher prevalence of several different cancers in BRCA mutation
carriers (Friedenson, 2007; Moran et al., 2012).
Genomic Context of Potential Somatic Amplifications
and Deletions
Next, we generated a genome-wide map of pSCNAnov and
pSCNAnbl as shown in Figures 2A and 2B. Although the
pSCNAsnorm were found throughout the genome, some regions
had recurrent pSCNAsnorm (clustered in megabase-scale re-
gions). For instance, chr1q32 and chr7q34 had recurrent dele-
tions in both peripheral blood and ovarian tissue, and the trendell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authors 1311
Figure 1. Summary of the Somatic Genomic Alterations in the Normal Tissues of the Ovarian Cancer Patients
(A) The pipeline for detecting somatic amplifications and deletions in apparently normal peripheral blood and ovarian cancer tissue of the TCGA ovarian cancer
patients.
(B) Summary statistics of somatic amplifications and deletions in peripheral blood and ovarian cancer tissue in the cohort. The BRCAmutation carriers are shown
categorically.
(C–E) The number of somatic genomic alterations (amplifications and deletions) per (C) peripheral blood sample, grouped according to the age of the individuals;
(D) peripheral blood sample, grouped according to BRCA mutation status; and (E) ovarian tissue sample, grouped according to BRCA mutation status. The
horizontal line shows the median value across all the samples in the respective panels.was independent of BRCAmutation status. Chr14q11.2, which is
close to the centromere, had a striking excess of amplifications
in ovarian tissue. In contrast, chr7-telomere proximal regions
had frequent deletions only in the peripheral blood of BRCA
mutation carriers. Whereas most of the individuals had small
number of detectable pSCNAsnorm, some others had consider-
able numbers of such events (see Supplemental Module 4 for
specific examples). Several of these candidate regions also
had similar patterns of copy number alterations in single-cell-
sequencing data (HCC38 cell line; Figure S4 of Voet et al., 2013).
We then surveyed the genomic context of the pSCNAsnorm.
We overlaid several different genomic features (Table 1), calcu-
lated the overlap with the pSCNAsnorm, and then compared the
observed overlap with that expected by chance using permuta-
tion (Experimental Procedures).We found that pSCNAsnormwere
slightly guanine-cytosine (GC) rich compared to the genome-
wide average; moreover, the pSCNAsnorm showed enrichment
for potential G-quadruplex motifs and Alu elements but were
depleted in evolutionarily conserved and L2 elements (Table 1;
Supplemental Module 4). Some of these trends were significant
for potential somatic amplifications or deletions only. Given
the challenges while combining heterogeneous data types and
designing the ideal null model for estimating statistical sig-
nificance (De et al., 2013), we cautiously interpret the data.
Nevertheless, our findings are consistent with the reports1312 Cell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authorsthat G-quadruplex (G4) motifs are frequently associated with
genomic alterations (Maizels and Gray, 2013; Tarsounas and
Tijsterman, 2013) and that Alu and L1 elements are active during
early development and contribute to mosaicism (Kano et al.,
2009; Macia et al., 2011; van den Hurk et al., 2007). However,
pSCNAsnorm, unlike genomic alterations found in cancer ge-
nomes (De andMichor, 2011; Durkin andGlover, 2007; Pedersen
and De, 2013), did not show any significant preference for
fragile sites. That led us to compare the genomic landscape of
somatic amplifications and deletions between normal and tumor
genomes.
Comparing Mutational Landscapes of Tumor and
Matched Normal Genomes
We overlaid the sites of frequent amplifications (pAmp) and de-
letions (pDel) in somatic tissues in our analysis (e.g., chr1q32,
chr3q29, chr7q34, chr14q11.2, chr15q11.2, and chr17q21)
with the pan-cancer Genomic Identification of Significant Tar-
gets in Cancer (GISTIC) peaks (sites of significantly recurrent
amplifications and deletions in multiple cancer types; Figure 2C),
which were identified based on nearly 3,000 samples from 26
cancer types (Beroukhim et al., 2010). We found that chr7q34,
which harbor T cell receptor locus, was a site of recurrent dele-
tion both in tumor and apparently normal tissue (peripheral blood
and also ovarian tissue). Error-prone DNA repair could be a
Figure 2. Genomic Landscape of the Somatic Genomic Alterations in the Normal Tissues
(A and B) Genome-wide mutational landscape showing pSCNAnorm (amplifications, blue; deletions, red) in apparently normal (A) ovarian cancer tissue and (B)
peripheral blood of the ovarian cancer patients. Each row represents an individual. Chromosomes are indicated below. Faint vertical lines in each chromosome
indicate centromere. Only the individuals with at least one detectable pSCNAnorm in the cohort are shown. The individuals with germline BRCA1 or BRCA2
mutations are shown separately.
(C) Comparing the mutation landscape of apparently normal peripheral blood with that of 26 different cancer types combined, as analyzed by Beroukhim et al.
(2010). The balance of blue and red shades indicates the proportion of amplifications and deletions. Heights of the bars indicate prevalence of such events in the
genome.source of genomic instability in these regions. Several of the
other sites of frequent amplifications (pAmp) and deletions
(pDel) in somatic tissues were proximal to minor GISTIC peaks.
For instance, the pan-cancer GISTIC peaks at chr1q32,
chr14q11.2, and chr15q11.2 map to cancer-associated genes
such as MDM4, BCL2L2, and A26B1, whereas the chr17q21
GISTIC peak marked NGFR, PHB, and CNP (Beroukhim et al.,
2010). Whereas none of these genes was recurrently affected
by pSCNAnorm, frequent genomic alterations in their genomic
neighborhood in apparently normal samples might reflect signa-
tures of selection or inherent genomic instability present in these
regions.
Genes Recurrently Amplified or Deleted in Multiple
Subjects
Several genes were affected by pSCNAsnorm in multiple individ-
uals as shown in Table 2. The affected genes were enriched forCsignaling and regulation-related function (hypergeometric test;
p value < 0.05); the statistical significance was modest due to
the size of the data set. For instance, PPP1R12B, which encodes
for a myosin phosphatase and plays a role in interleukin-
signaling pathway (Bannert et al., 2003) was hemizygously
deleted in more than 8% of the normal peripheral blood
and ovarian tissue samples. Deletion of complement factors
CFHR1 and CFHR3 is known to be associated with defective
complement regulation in blood, atypical hemolytic uremic syn-
drome, and macular degeneration (Hughes et al., 2006; Zipfel
et al., 2007). Notably, these genes are consistently deleted, not
amplified (false-discovery-rate-corrected p value using binomial
test in blood; PPP1R12B: 6.81 3 109, CFHR3: 5.65 3 104,
CFHR1: 5.6 3 104; Table 2), raising the possibility that
these genes might be under directional selection in apparently
normal peripheral blood. DUSP22 is a phosphatase known to
interact with mitogen-activated protein kinase pathway (Huangell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authors 1313
Table 1. Overlap between Different Genomic Features and pSCNAsnorm
Genomic Feature Data Source Enrichment
q Value of
Enrichment
28-way conserved elements UCSC Genome Browser (Miller et al., 2007) enriched <0.05
L2 elements UCSCGenomeBrowser (Meyer et al., 2013) enriched <0.05
Alu elements UCSCGenomeBrowser (Meyer et al., 2013) depleted <0.05
G-quadruplex motifs (Huppert and Balasubramanian, 2005) depleted <0.05
L1 elements UCSCGenomeBrowser (Meyer et al., 2013) – >0.05
GC content UCSCGenomeBrowser (Meyer et al., 2013) – >0.05
Protein-coding genes ENSEML (Flicek et al., 2014) – >0.05
Constant early replicating regions (Hansen et al., 2010) – >0.05
Constant late replicating regions (Hansen et al., 2010) – >0.05
Early replicating fragile sites (Barlow et al., 2013) – >0.05
Common fragile sites (Durkin and Glover, 2007) – >0.05
For more details, please see Figure S4.et al., 2012) and implicated in different cancer types including he-
matopoietic malignancies. ZBTB34 is a transcriptional repressor
broadly expressed in many tissue types and might have a role in
recruitment of HDAC (Qi et al., 2006). Protocadherin PCDHA13
plays a role in cell adhesion and signaling. Several other genes
that were affected by pSCNAsnorm in >1% of the samples (e.g.,
LRP5L, PPYR1, SIRPB1, etc.) are also involved in signaling.
Further work is necessary to ascertain the consequences of
these genetic changes in the normal peripheral blood and
ovarian tissue and also to assess whether impaired function of
these genes affect tumor-related inflammation response, tumor
maintenance, and growth signals.
Patients with More pSCNAs Have Poor Survival
It is poorly understood whether somatic genomic alterations
in apparently normal tissue can impact cancer development
(e.g., as by influencing selection for driver mutations or other-
wise influencing evolutionary trajectories of cancer genomes),
which would influence overall patient survival. Somatic genomic
alterations in normal tissues could be symptomatic of systemic
issues, from generalized genomic instability, immune dysfunc-
tion, to impaired tissue fitness, which could substantially alter
cancer evolution. The frequencies of genomic alterations in
normal tissue did not immediately predict the burden of
genomic alterations (i.e., point mutations, copy number alter-
ations, and loss of heterozygosity events; Supplemental
Module 5) in the matched tumor genomes. However, analyzing
somatic point mutations of known cancer genes, we found that
the individuals with no detectable pSCNAsnbl in peripheral
blood had more cancer gene mutations compared to those
with a higher frequency (greater than or equal to four
pSCNAsnbl; p value: 5.85 3 102) of detectable pSCNAnbl.
Moreover, mutations in RB1, MLL3, and CREBBP were present
in >5% of the ovarian tumor samples with no detectable
pSCNAnbl but rarely occurred in the tumor samples with an
excess of pSCNAsnbl (Figure 3A; sample size is insufficient for
statistical testing). The results were consistent irrespective of
the cutoff chosen and other potential covariates (Supplemental
Module 5).1314 Cell Reports 7, 1310–1319, May 22, 2014 ª2014 The AuthorsWe then compared the survival characteristics of the ovarian
cancer patients with high number of amplifications and deletions
in apparently normal peripheral blood (pSCNAsnbl R 4) against
those who have apparently more-normal, diploid genome (no
detectable pSCNAsnbl), after excluding the patients with BRCA
mutations. There was a significant negative correlation between
the number of pSCNAnbl events and survival (Spearman rank
correlation coefficient: 0.20; p value: 1.92 3 102). Using
Kaplan Meier survival analysis, we found that the patients with
greater than or equal to four pSCNAsnorm in peripheral blood
had significantly shorter survival (log rank test; p value: 3.64 3
104; Figure 3B) compared to those with no pSCNAs detected
in blood. The results were not biased by age, stage, tumor purity,
and remained consistent for alternative pSCNA thresholds (Sup-
plemental Module 5). Taken together, our findings suggest that
the burden of somatic amplifications and deletions in normal
peripheral blood predicts clinical outcome.
Analysis of a TCGA Lung Cancer Data Set
We extended the key analyses to the TCGA lung squamous cell
carcinoma data set (Cancer Genome Atlas Research Network,
2012). There were 110 samples that had copy number status
interrogated using two independent centers; we analyzed these
samples in our study. Of these, 18 and 92 samples had periph-
eral blood and lung tissue as the matched normal tissues,
respectively. We found that the number of somatic genomic
alterations detectable at a tissue-level resolution was compara-
ble to that reported in Figure 1, although slightly lower; this is
probably due to the fact that the patients in this cohort are rela-
tively younger compared to the ovarian cancer cohort (Supple-
mental Module 6). Furthermore, the number of pSVNAsnorm
increased with age, and some genomic regions (e.g., chr1q32,
chr15q11, and chr17q21) had clusters of pSCNAsnorm in this
cohort as well (Supplemental Module 6).
DISCUSSION
Our analysis provides a generation survey of the patterns of so-
matic amplifications and deletions in apparently normal human
Table 2. The List of Genes Affected by Recurrent Events of Somatic Amplifications and Deletions in Apparently Normal Peripheral
Blood and Ovarian Tissue
Gene Name Chromosomal Position Chromosome Band
Number of Samples with pSCNA
Total
(pAmpbl, pDelbl),
(pAmpov, pDelov)
PPP1R12B chr1:200584459-200824320:1 chr1q32.1 34 (0, 26), (0, 9)
CFHR3 chr1:195010553-195031160:1 chr1q31.3 16 (1, 13), (0, 2)
DUSP22 chr6:237101-296353:1 chr6p25.3 15 (2, 9), (2, 3)
CFHR1 chr1:195055484-195067940:1 chr1q31.3 12 (0, 10), (0, 2)
ZBTB34 chr9:128662765-128687978:1 chr9q33.3 7 (4, 0), (0, 3)
PCDHA13 chr5:140215818-140372113:1 chr5q31.3 7 (0, 4), (3, 0)
LRP5L chr22:24077424-24131324:-1 chr22q11.23 7 (4, 0), (3, 0)
SIRPB1 chr20:1493029-1548689:-1 chr20p13 6 (2, 1), (3, 0)
PPYR1 chr10:46503540-46508326:1 chr10q11.22 6 (5, 0), (1, 0)
NUP210L chr1:152231790-152394216:-1 chr1q21.3 6 (0, 2), (0, 4)
IGHV1-68 chr14:106230914-106231208:-1 chr14q32.33 6 (5, 0), (1, 0)
GSTT1 chr22:22706142-22714271:-1 chr22q11.23 6 (4, 0), (2, 0)
SPAG11 chr8:7292686-7308602:-1 chr8p23.1 5 (4, 1), (0, 0)
IGHVII-40-1 chr14:105967906-105967963:-1 chr14q32.33 5 (0, 5), (0, 0)
IGHV3-41 chr14:105970089-105970538:-1 chr14q32.33 5 (0, 5), (0, 0)
FAM90A7 chr8:7401070-7406305:-1 chr8p23.1 5 (4, 1), (0, 0)
FAM90A23 chr8:7424014-7429245:-1 chr8p23.1 5 (4, 1), (0, 0)
FAM90A22 chr8:7416365-7421601:-1 chr8p23.1 5 (4, 1), (0, 0)
DEFB4 chr8:7789609-7791647:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB107B chr8:7340778-7354243:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB107A chr8:7706652-7710648:-1 chr8p23.1 5 (4, 1), (0, 0)
DEFB106B chr8:7327436-7331319:-1 chr8p23.1 5 (4, 1), (0, 0)
DEFB106A chr8:7720104-7723985:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB105B chr8:7332649-7334483:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB105A chr8:7716940-7718774:-1 chr8p23.1 5 (4, 1), (0, 0)
DEFB104B chr8:7315236-7320014:-1 chr8p23.1 5 (4, 1), (0, 0)
DEFB104A chr8:7731403-7736178:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB103B chr8:7776136-7777515:1 chr8p23.1 5 (4, 1), (0, 0)
DEFB103A chr8:7273901-7275280:-1 chr8p23.1 5 (4, 1), (0, 0)
Several of these genes are in the defensin gene cluster.tissue types of patients with cancer. We found, on average, two
to four potential somatic amplifications and deletions per normal
sample detectable at a tissue-level resolution, although there
were considerable interindividual variations. The burden of
such genomic changes increased with age, and BRCA mutation
carriers harbored such events at a greater frequency than non-
carriers. It is possible that germline mutations in other genes
(e.g., ATM, RAD51, and TP53) also increase the prevalence of
potential somatic genomic alterations in apparently normal tis-
sues, but the TCGA data set was not suitable to examine that
possibility systematically. Some genomic regions have clusters
of recurrent genomic alterations, the footprint of which could
be found even in the genomes of several different types of
cancer—indicating that genomic alterations in these regions
might predate tumor initiation. Many of the genes affected by
recurrent somatic amplifications and deletions (pSCNAsnorm)
were associated with signaling and regulation. Interestingly,Cthe frequency of pSCNAsnorm significantly predicted survival
patterns of these cancer patients. We propose that somatic
genomics are common in apparently normal tissues and have
implications for complex diseases.
We note the advantages and potential caveats of our study
design to provide a balanced perspective. We chose to focus
on the pSCNAsnorm that are detectable at tissue-level resolution,
because these genetic changesmight have noticeable effects on
tissue-level function. The copy number calls using two indepen-
dent arrays led to detection of high-confidence pSCNAnorm
events, but those with inconsistent array comparative genomic
hybridization (aCGH) calls were missed. Additionally, we could
not detect the events that were small (102 bp or smaller), had
low signal-to-noise ratio, occurred in a minor subpopulation of
cells, or were masked by copy number changes in matched
tumor samples. Therefore, the frequencies of somatic genomic
alterations reported here probably represent the lower boundell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authors 1315
Figure 3. Significance of the Somatic
Genomic Alterations in the Normal Tissues
(A) Frequency of the common cancer gene muta-
tions in ovarian cancer patients who had no
pSCNAbl (black) and those who haveR4 pSCNAbl
(grey).
(B) Kaplan Meier curve showing difference in
the survival patterns between the ovarian cancer
patients who have no pSCNAbl (black) and those
who have R4 pSCNAbl (red). The difference
was statistically significant (log rank test, p value
3.64 3 10-4).of such events in apparently normal tissues. Future assessments
based on genome sequencing would be able to overcome many
of these limitations. Even then, our estimates of the absolute fre-
quency and the rate of such events per locus per somatic cell
division were consistent with that reported elsewhere, including
single-cell-based estimates (Campbell and Eichler, 2013; Ja-
cobs et al., 2012; Laurie et al., 2012; Lupski, 2007; Voet et al.,
2013). We could not determine whether the pSCNAsnorm repre-
sented different subclones leading to genetic heterogeneity in
the normal tissue samples. Whereas the genomic alterations in
peripheral blood were accumulated over the lifetime of the indi-
vidual, those in the ovarian tissue were accrued after the time of
separation of the normal and tumor stem cell, which is unknown
and could precede or follow the first driver event in tumorigen-
esis. Therefore, we recommend caution when analyzing and
interpreting the pSCNAsnov data.
Our findings concur with the emerging concept that appar-
ently normal somatic tissues also accumulate considerable
burden of somatic mutations (Abyzov et al., 2012; Biesecker
and Spinner, 2013; De, 2011) and that genomic alterations in
some chromosomal regions might predate tumor initiation
(Konishi et al., 2011; Tomasetti et al., 2013). We found that the
pSCNAsnorm were enriched for G4 motifs and Alu elements
(and also showedweak preference for L1 elements) but depleted
for evolutionarily conserved elements. Both L1 and Alu elements
are known to be active in embryonic stem cell and during early
development in the human genome (Macia et al., 2011; van
den Hurk et al., 2007), giving rise to mosaicism (De, 2011;
Kano et al., 2009). Alu retrotransposition is mediated by active
L1 elements, suggesting that these two mutagenic processes
in somatic cells could be linked (Dewannieux et al., 2003).
Emerging reports show that G4 structures are stable and detect-
able in the human genome (Lam et al., 2013) and that these
elements play roles in genomic alterations (Kruisselbrink et al.,
2008; Maizels and Gray, 2013; Tarsounas and Tijsterman,
2013). In the light of these reports, it is tempting to propose the
likely origins of the pSCNAsnorm, but further work needs to be
done to infer causality beyond correlation. During development
and aging, random drift can also lead to a scenario where a small
number of clones contribute to the bulk of the cells, as reported
elsewhere (Clemente et al., 2011; Elson et al., 2001). Given their
poor overlap with evolutionarily conserved elements, most of
the pSCNAsnorm, especially those outside the hot spots, are ex-1316 Cell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authorspected to be neutral. Recurrent genomic changes, especially
those that are detectable at a tissue-level resolution (e.g.,
pSCNAsnbl) and occur near genes involved in signaling and regu-
lation, might indicate potential natural selection promoting the
clones that harbor these changes. Of course, these different
factors can also operate in combination to lead to the observed
genome-wide patterns. In any case, the fact that some of the
genomic regions amplified and deleted in tumor samples were
also recurrently and independently altered in normal somatic tis-
sue is likely to bring new challenges for diagnosis, drug develop-
ment, and prognosis. For instance, in liquid biopsies, it might
introduce additional difficulties to ascertain the cell of origin of
the copy of cell-free DNA carrying certain mutations. Further-
more, our findings raise a fresh debate regarding what should
be considered as a reference normal tissue.
Whereas decades of research has predominantly focused on
tumor cells or microenvironment in their immediate vicinity, we
present a provocative hypothesis that genomic landscape of
apparently normal tissue such as peripheral blood might also
have implications for the course of tumor progression and asso-
ciated clinical outcome. Individuals with more somatic genomic
alterations are at a greater cancer risk as reported elsewhere
(Jacobs et al., 2012; Laurie et al., 2012) and have poorer survival
than others, as shown here. One might argue that increased fre-
quencies of pSCNAs in normal tissues reflect a general genomic
instability (e.g., in ovary in the current study), which impacts
tumor development; e.g., increased cancer risk and an excess
of somatic genomic alterations in apparently normal tissue in
BRCA mutation carriers (Friedenson, 2007; Konishi et al., 2011;
Moran et al., 2012) support this concept. Another possible expla-
nation for the correlation between pSCNAnorm and the cancer
phenotype could be that abnormal signaling/function in blood
or peripheral tissue might impair normal anticancer defenses
(such as immunity; Hanahan and Weinberg, 2011); genomic
alterations involving signaling genes in peripheral blood are
consistent with this idea. Finally, an alternative (and not neces-
sarily mutually exclusive) hypothesis is that increased fre-
quencies of pSCNAnorm reflect reductions in the overall fitness
of somatic tissues, which can increase selection for particular
adaptive mutations, thus facilitating clonal selection for neo-
plastic cells with these adaptive driver mutations (contributing
to poorer survival and increased incidence of cancer in
older individuals; DeGregori, 2011, 2013). We suspect that any
individual patient probably experiences a combination of these
effects. Taken together, our findings suggest that somatic ampli-
fications and deletions are common in apparently normal human
tissues and can have consequences for complex diseases such
as cancer.
EXPERIMENTAL PROCEDURES
Data Sets
Data on genomic alterations and clinical parameters for the lung and ovarian
cancer patients were obtained from the TCGA (Cancer Genome Atlas
Research Network, 2011, 2012). In the TCGA initiative, copy number
status for ovarian tumor-normal pairs was determined using different arrays
in two genome analysis centers: Agilent HG-CGH-415K_G4124A and
HG-CGH-244A arrays at Harvard Medical School and Agilent CGH-
1x1M_G4447A array at Memorial Sloan Kettering Cancer Center. We
analyzed the aCGH-based copy number status of 423 serous ovarian cancer
samples and matched normal tissues (healthy ovarian tissue or peripheral
blood), for which copy number calls were available using two independent
arrays. Of them, 109 and 314 samples had normal ovarian tissue and periph-
eral blood as matched normals, respectively. In the cohort 27, 10, 20, and 9
patients had BRCA1 germline mutations, BRCA1 somatic mutations, BRCA2
germline mutations, and BRCA2 somatic mutations, respectively. Of the
samples, TCGA-13-1512 had germline mutations in both BRCA1 and
BRCA2, whereas TCGA-23-1026 had somatic mutation in BRCA1 and germ-
line mutation in BRCA2. These patients were of age 26–89 years, with a
median of 58 years.
Detection of Somatic Copy Number Status
The arrays used in the TCGA initiative had kb-level resolution, and thus, smaller
amplifications and deletions were not detected. We determined somatic
genomic alterations in apparently normal human tissues as follows: (1) a
genomic region was flagged to have somatic amplification in a normal sample
if this region had log2 signal-to-noise ratio >0.2 in the normal tissue and log2
signal-to-noise ratio <0.1 (copy neutral or deletion) in tumor tissue, supported
by both the arrays. (2) Conversely, a genomic region was flagged to have
somatic deletion in a normal sample if it had log2 signal-to-noise ratio <0.2
in the normal tissue but log2 signal-to-noise ratio >0.1 (copy neutral or ampli-
fication) in tumor tissue, again supported by both the arrays. Sex chromo-
somes were not analyzed. Moreover, these arrays typically do not cover the
centromere regions and the tips of the telomeres, so we could not assess
those regions for copy number status. Therefore, our estimation probably pre-
sents very conservative estimates of the number of somatic genomic alter-
ations in these samples.
As detailed in the Supplemental Module 1, we performed extensive quality
control steps, (1) excluding the tumor-normal pairs for which there were
poor agreements in copy number calls between the pairs of aCGH arrays,
(2) excluding those genomic alterations that overlap with the common
copy number variations present in the human population, and (3) excluding
outlier samples (e.g., TCGA-13-0797) that had an excess of genomic
alteration calls in somatic tissue. The excess of somatic amplification or dele-
tion calls in these samples could be genuine—indicating extensive DNA
damage and/or defects in DNA repair; alternately, their copy number calls
could be affected by unique patterns of amplifications and deletions in the
cancer genome or technical problems associated with the copy number
calls in those samples. We were unable to differentiate between these pos-
sibilities and thus chose to exclude these outlier samples. Anyhow, exclusion
of these samples minimized the concern that individual outliers could bias
our overall results. We applied additional filters to ensure that these events
were not due to compensatory genomic alterations in the tumor genome
(Supplemental Module 1). Furthermore, tumor purity had only minor effects
on our analysis (Supplemental Module 1). But we cannot rule out the possi-
bilities of any false positives in our data set. Our filtered data set had 607
potential somatic amplifications and deletions in 314 normal peripheral blood
samples and 494 somatic amplifications and deletions in 109 normal ovarian
tissue samples.CMutation Rate Estimation
We estimated the rate of somatic amplification and deletion in the blood
using two models. In the first model, which follows a discrete-time pure
birth stochastic process (Galton-Watson process with zero death rate), the
mutation rate per locus per symmetric division r is roughly estimated as
r =
NL
33 109
1
2
a
 1
;
where N and L are the frequency and median length of the detectable somatic
copy number alterations per blood sample and a is the fraction of cells where
the genomic alterations were detected.
In the second model, we consider the possibility of cellular death and relax
the assumption of simultaneous generations. In this model, which uses a
continuous-time binary-branching process, the mutation rate per locus per
symmetric division r is roughly estimated as
r =
NL
33 109
b d
b
 a
1 a

;
where b and d are the birth and death rate of the hematopoietic stem cell. Both
models were basic, in a sense that we did not consider tissue composition,
challenges while detecting somatic copy number status using arrays, and
complex developmental trajectories of various cell types, which are often
poorly understood. Please see Supplemental Module 2 for details of the
calculation and the underlying assumptions.
Genomic Context Analysis
We also obtained the genomic coordinates of genes and other genomic
features based on the human reference genome version hg18 from the Uni-
versity of California, Santa Cruz (UCSC) Genome Browser (Meyer et al.,
2013). In particular, we analyzed data for protein-coding genes (Flicek
et al., 2014), evolutionarily conserved elements (UCSC Genome Browser;
28_way_conservaton track; Miller et al., 2007), repeat elements (Meyer
et al., 2013), potential G4-forming motifs (Huppert and Balasubramanian,
2005), early and late DNA replication patterns conserved across tissue types
(Hansen et al., 2010), and common and early replicating fragile sites (Barlow
et al., 2013; Durkin and Glover, 2007); these features were previously shown
as being associated with local mutation patterns in the human genome (Pang
et al., 2013; Podlaha et al., 2012; Yang et al., 2013). Some genomic regions
replicate early (or late) in all human cell types, whereas other genomic re-
gions show variable replication timing across different cell types (Hansen
et al., 2010). We have only analyzed genomic regions whose replication
timing patterns were deemed cell-type invariant (Hansen et al., 2010), but
we can’t rule out the possibilities that some of those regions might have
different replication timing in certain blood or ovarian cell type. We obtained
the UCSC data using CruzDB (Pedersen et al., 2013b) and calculated
the extent of overlap between these genomic features and pSCNAnorm and
their likely statistical significance using different scripts in Bedtools (Quinlan
and Hall, 2010). For each normal sample, we first calculated the extent of
overlap using IntersectBed after masking selected regions: 1 Mb centering
centromeres, 500 kb from the tip of the telomeres, and also the genomic
regions that underwent copy number changes in its matched tumor
genome (and thus was not assessed for copy number status in the paired
normal sample). We then permuted the pSCNAsnorm within respective chro-
mosomes using ShuffleBed, while keeping the location and higher-order
organization of genomic features unchanged and after masking the same
selected regions in each sample. We repeated the permutation for 103 times,
counting the number (n) of simulated overlap greater than the observed one,
after aggregating the results over the data set, and converted that to q value
(q value = n/103).
While comparing the landscape of genomic alterations in tumor and normal
genomes, we divided the human reference genome into 1 Mb nonoverlapping
blocks and counted the number of amplification and deletion events in each
block. We also collected the pan-cancer GISTIC peaks identified based on
nearly 3,000 samples from 26 cancer types (Beroukhim et al., 2010). Weell Reports 7, 1310–1319, May 22, 2014 ª2014 The Authors 1317
plotted a scaled version of the log(p value) of significance of these GISTIC
peaks as a proxy for the abundance of amplifications and deletions in cancer
genomes.
Cancer Gene Mutation Analysis
We obtained data on somatic point mutations in protein coding genes for the
ovarian cancer samples from the TCGA (Cancer Genome Atlas Research
Network, 2011). The variants were identified using Illumina GaII and ABI SOLiD
sequencing and then comparing tumor andmatched normal samples as a part
of the TCGA initiative. We analyzed the potentially functional mutations, i.e.,
missense, nonsense, frameshift, and splice-site mutations, that occurred
in the set of 121 classic cancer genes (definition: the COSMIC database). A
vast majority of these were missense mutations.
Survival Analysis
We obtained survival data (days_to_death) for these samples from the TCGA
(Cancer Genome Atlas Research Network, 2011). Survival analysis was per-
formed using Kaplan Meier plot and log rank test. The samples for which sur-
vival data were not available were censored.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six supplemental modules, eleven figures,
and two tables and can be found with this article online at http://dx.doi.org/10.
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